Rare variants in cholesterol transporter genes in patients with lipid metabolism disorders

Cardiovascular diseases are the leading cause of death both in Russia and in the world. One of the factors predisposing to the development of cardiovascular diseases is lipid metabolism disorders (dyslipidemias), which contribute to the progression of atherosclerosis. Currently, there are known genes associated with the development of monogenic forms of lipid metabolism disorders characterized by marked changes in lipid levels. However, identifying individuals with an increased genetic risk of dyslipidemia remains an unsolved problem, due to the polygenic nature of most cases. The aim of this work was to study the spectrum of rare variants in the cholesterol transporter genes ABCA1, ABCG1, ABCG5, ABCG8 and NPC1L1 that occur in patients with lipid metabolism disorders in the population of the Northwestern region of Russia. The search for rare variants (gnomAD frequency less than 1 %) in the ABCA1, ABCG1, ABCG5, ABCG8 and NPC1L1 genes was performed using targeted sequencing data for 169 patients with lipid metabolism disorders. 14 variants were identified in the ABCA1 gene (17 patients); 4 variants, in the ABCG1 gene (5 patients); 11 variants, in the ABCG5 gene (18 patients); and 7 variants, in the ABCG8 gene (11 patients). The frequency of some of them, according to the RUSeq database, is higher than in the global population. 19 patients (11 %) were carriers of the p.(Val177Ile)/p.(His221Tyr)/p.(Ala271Phe) haplotype in the NPC1L1 gene, which may be specific to the Russian population, meaning that these variants are not rare, but polymorphic, and occur more frequently in patients with impaired lipid metabolism. Influence of the p.(Val177Ile) variant of the NPC1L1 gene on the development of atherosclerosis was assessed using additional sample sets (a group of patients with atherosclerosis, a control group), but no significant differences in genotype frequencies were revealed. Thus, at present, there are insufficient data to support the role of the p.(Val177Ile)/p.(His221Tyr)/p.(Ala271Phe) haplotype of the NPC1L1 gene in the development of dyslipidemia and atherosclerosis. The study draws attention to the population specificity of a number of variants in cholesterol transporter genes, in particular in the NPC1L1 gene, for the Northwestern region of Russia. The data can be further used for design and calculation of genetic risk scores for dyslipidemia.

1. Averkova A.O., Brazhnik V.A., Speshilov G.I., Rogozhina A.A., Koroleva O.S., Zubova E.A., Galyavich A.S., Tereshenko S.N., Boyeva O.I., Zateyshchikov D.A. Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome. Bull Rus State Med Univ. 2018;5:80-86. doi 10.24075/brsmu.2018.061

2. Barbitoff Y.A., Khmelkova D.N., Pomerantseva E.A., Slepchen kov A.V., Zubashenko N.A., Mironova I.V., Kaimonov V.S., … Aseev M.V., Shcherbak S.G., Glotov O.S., Isaev A.A., Predeus A.V. Expanding the Russian allele frequency reference via cross-laborato ry data integration: insights from 7452 exome samples. Natl Sci Rev. 2024;11(10):nwae326. doi 10.1093/nsr/nwae326

3. Chubykina U., Vasiluev P., Ivanova O., Ezhov M. The mysterious masks of hypercholesterolemia: a unique clinical case. Circulation. 2025; 151(11):799-803. doi 10.1161/CIRCULATIONAHA.124.071638

4. Cross B., Turner R., Pirmohamed M. Polygenic risk scores: an over view from bench to bedside for personalised medicine. Front Genet. 2022;13:1000667. doi 10.3389/fgene.2022.1000667

5. Danilova I., Rau R., Barbieri M., Grigoriev P., Jdanov D.A., Meslé F., Vallin J., Shkolnikov V.M. Subnational consistency in cause-of-death data: the cases of Russia, Germany, the United States, and France. Population. 2021;76(4):645-674. doi 10.3917/popu.2104.0693

6. Ezhov M.V., Bazhan S.S., Ershova A.I., Meshkov A.N., Soko lov A.A., Kukharchuk V.V., Gurevich V.S., … Balakhonova T.V., Filippov A.E., Akhmedzhanov N.M., Aleksandrova O.Yu., Lipovetsky B.M. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58-98 (in Russian)

7. Fan H.Y., Tsai M.C., Lai C.J., Yeh C.L., Hsu H.Y., Lai P.J., Hsu H.C., Su T.C., Lin H.J., Lin Y.F., Lu T.P., Chien K.L. Genetic variants in severe hypertriglyceridemia among Taiwanese participants – insights from genome-wide association and whole-exome sequencing analyse. Circ J. 2025;89(3):331-339. doi 10.1253/circj.CJ-24-0491

8. Fath F., Bengeser A., Barresi M., Binner P., Schwab S., Ray K.K., Krämer B.K., Fraass U., März W. FH ALERT: a feasibility study of a novel approach to identify patients with familial hypercholesterolemia. Res Square. 2020. doi 10.21203/rs.3.rs-108034/v1

9. Futema M., Shah S., Cooper J.A., Li K.W., Whittall R.A., Sharifi M., Goldberg O., … Roeters van Lennep J.E., Sijbrands E.J.G., Whit taker J.C., Talmud P.J., Humphries S.E. Refinement of variant selec tion for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replica tion in samples from 6 countries. Clin Chem. 2015;61(1):231-238. doi 10.1373/clinchem.2014.231365

10. Ghaleb Y., Elbitar S., Philippi A., El Khoury P., Azar Y., Andrianiri na M., Loste A., … Deleuze J.F., Rabès J.P., Boileau C., Abifadel M., Varret M. Whole exome/genome sequencing joint analysis of a fami ly with oligogenic familial hypercholesterolemia. Metabolites. 2022; 12(3):262. doi 10.3390/metabo12030262

11. Hegele R.A., Ban M.R., Cao H., McIntyre A.D., Robinson J.F., Wang J. Targeted next-generation sequencing in monogenic dyslipidemias. Curr Opin Lipidol. 2015;26(2):103-113. doi 10.1097/MOL.0000000000000163

12. Heidemann B.E., Koopal C., Baass A., Defesche J.C., Zuurbier L., Mulder M.T., Roeters van Lennep J.E., Riksen N.P., Boot C., Marais A.D., Visseren F.L.J. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene. Clin Genet. 2022;102(4):253-261. doi 10.1111/cge.14185

13. Heron M. Deaths: leading causes for 2018. National Vital Stat Rep. 2021;70(4):1-115. doi 10.15620/cdc:10418690

14. Hindy G., Dornbos P., Chaffin M.D., Liu D.J., Wang M., Sel varaj M.S., Zhang D., … Willer C.J., Natarajan P., Flannick J.A., Khera A.V., Peloso G.M. Rare coding variants in 35 genes as sociate with circulating lipid levels – a multi-ancestry analysis of 170,000 exomes. Am J Hum Genet. 2022;109(1):81-96. doi 10.1016/j.ajhg.2021.11.021

15. Hu M., Yang F., Huang Y., You X., Liu D., Sun S., Sui S.F. Structural in sights into the mechanism of human NPC1L1-mediated cholesterol uptake. Sci Adv. 2021;7(29):eabg3188. doi 10.1126/sciadv.abg3188

16. Ivanova O.N., Vasiliev P.A., Zakharova E.Y. Molecular basis of primary monogenic dyslipidemia. Medical Genetics. 2020;19(12):4-17. doi 10.25557/2073-7998.2020.12.4-17 (in Russian)

17. Kalwick M., Roth M. A comprehensive review of the genetics of dyslipidemias and risk of atherosclerotic cardiovascular disease. Nutrients. 2025;17(4):659. doi 10.3390/nu17040659

18. Koseki M., Yamashita S., Ogura M., Ishigaki Y., Ono K., Tsukamoto K., Hori M., Matsuki K., Yokoyama S., Harada-Shiba M. Current diagnosis and management of tangier disease. J Atheroscler Thromb. 2021;28(8):802-810. doi 10.5551/jat.RV17053

19. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Bub nova M.G., Balakhonova T.V., Gurevich V.S., … Sokolov A.A., Sumarokov A.B., Gornyakova N.B., Obrezan A.G., Shaposhnik I.I. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII re vision. J Atherosclerosis Dyslipidemias. 2020;1(38):7-40. doi 10.34687/2219-8202.JAD.2020.01.0002 (in Russian)

20. Li W., Wang Y., Huang R., Lian F., Xu G., Wang W., Xue S. Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease. BMC Cardiovasc Disord. 2024;24(1):97. doi 10.1186/s12872-024-03759-5

21. Liao J., Yang L., Zhou L., Zhao H., Qi X., Cui Y., Ouyang D. The NPC1L1 gene exerts a notable impact on the reduction of lowdensity lipoprotein cholesterol in response to hyzetimibe: a facto rial-designed clinical trial. Front Pharmacol. 2022;13:755469. doi 10.3389/fphar.2022.755469

22. Mauriello A., Ascrizzi A., Molinari R., Falco L., Caturano A., D’Andrea A., Russo V. Pharmacogenomics of cardiovascular drugs for atherothrombotic, thromboembolic and atherosclerotic risk. Genes. 2023;14(11):2057. doi 10.3390/genes14112057

23. McPherson R., Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res. 2016;118(4):564-578. doi 10.1161/CIRCRESAHA.115.306566

24. Meašić A.M., Bobinec A., Sansović I., Boban L., Pavić A.M., Pušeljić S., Barišić I. 96 homozygous ABCG8 mutation in a 14-yearold boy with sitosterolemia. Arch Dis Child. 2021;106(Suppl.2): A1-A216

25. Medeiros A.M., Alves A.C., Miranda B., Chora J.R., Bourbon M., Rato Q., Gaspar A., … Correia S., Vassalo T., Pack T., Martins V., Vieira V.F. Unraveling the genetic background of individuals with a clinical familial hypercholesterolemia phenotype. J Lipid Res. 2024;65(2):100490. doi 10.1016/j.jlr.2023.100490

26. Meshkov A.N., Ershova A.I., Kiseleva A.V., Shalnova S.A., Drapki na O.M., Boytsov S.A.; on behalf of the FH-ESSE-RF investigators. The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian Federation: the FH-ESSE-RF study. J Pers Med. 2021;11(6):464. doi 10.3390/jpm11060464

27. Meshkov A.N., Kiseleva A.V., Yershova A.I., Sotnikova E.A., Smetnev S.A., Limonova A.S., Zharikova A.A., Zaichenoka M., Ramen sky V.E., Drapkina O.M. ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL gene variants and coronary artery disease risk. Russian Journal of Cardiology. 2022;27(10):2226. doi 10.15829/1560-4071-2022-5232 (in Russian)

28. Miroshnikova V.V., Pchelina S.N., Donnikov M.Yu., Vorobyev A.S., Tsai V.V., Kovalenko L.V., Glotov O.S. The NGS panel for genetic testing in cardiology: from the evaluation of disease risk to pharma cogenetics. Farmakogenetika i Farmakogenomika = Pharmacogenetics and Pharmacogenomics. 2023a;1:7-19. doi 10.37489/25880527-2023-1-7-19 (in Russian)

29. Miroshnikova V.V., Vasiluev P.A., Linkova S.V., Soloviov V.M., Ivanova O.N., Tolmacheva E.R., Udalova V.Y., … Grunina M.N., Smirnova N.N., Kuchina A.S., Zakharova E.Y., Pchelina S.N. Pe diatric patients with sitosterolemia: next-generation sequencing and biochemical examination in clinical practice. J Pers Med. 2023b; 13(10):1492. doi 10.3390/jpm13101492

30. Miroshnikova V.V., Izyumchenko A.D., Muzalevskaya M.V., Legostae va K.V., Grunina M.N., Dracheva K.V., Urazgildeeva S.A., Berkov ich O.A., Baranova E.I., Glotov O.S., Kulikov A.N., Gurevich V.S., Pchelina S.N. Genetic architecture of familial hypercholesterolemia: a cohort of St. Petersburg residents. Russian Journal of Cardiology. 2025;30(10):87-94. doi 10.15829/1560-4071-2025-6432 (in Russian)

31. Mokhtar F.B.A., Plat J., Mensink R.P. Genetic variation and intestinal cholesterol absorption in humans: a systematic review and a gene network analysis. Prog Lipid Res. 2022;86:101164. doi 10.1016/j.plipres.2022.101164

32. Musunuru K., Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579-585. doi 10.1161/CIRCRESAHA.115.306398

33. Pan-Lizcano R., Mariñas-Pardo L., Núñez L., Rebollal-Leal F., LópezVázquez D., Pereira A., Molina-Nieto A., Calviño R., VázquezRodríguez J.M., Hermida-Prieto M. Rare variants in genes of the cholesterol pathway are present in 60 % of patients with acute myo cardial infarction. Int J Mol Sci. 2022;23(24):16127. doi 10.3390/ijms232416127

34. Prasad K., Mishra M. Mechanism of hypercholesterolemia-induced atherosclerosis. Rev Cardiovasc Med. 2022;23(6):212. doi 10.31083/j.rcm2306212

35. Pshenichnikova I.I., Zakharova I.N., Korchagina Yu.V., Pupykina V.V., Okulova O.A., Teleznikova N.D., Vasiliev P.A., Ivanova O.N., Ba ranova P.V., Zakharova E.Yu., Ezhov M.V. Sitosterolemia (phytos terolemia): diagnosis, treatment, and prognosis. Meditsinskiy Sovet = Medical Council. 2024;18(19):198-205. doi 10.21518/ms2024-432 (in Russian)

36. Read R.W., Schlauch K.A., Lombardi V.C., Cirulli E.T., Washing ton N.L., Lu J.T., Grzymski J.J. Genome-wide identification of rare and common variants driving triglyceride levels in a Nevada popula tion. Front Genet. 2021;12:639418. doi 10.3389/fgene.2021.639418

37. Reeskamp L.F., Volta A., Zuurbier L., Defesche J.C., Hovingh G.K., Grefhorst A. ABCG5 and ABCG8 genetic variants in familial hyper cholesterolemia. J Clinical Lipidology. 2020;14(2):207-217.e7. doi 10.1016/j.jacl.2020.01.007

38. Ripatti P., Rämö J.T., Söderlund S., Surakka I., Matikainen N., Pirinen M., Pajukanta P., … Wilson R.K., Palotie A., Freimer N.B., Taskinen M.R., Ripatti S. The contribution of GWAS loci in familial dyslipidemias. PLoS Genet. 2016;12(5):e1006078. doi 10.1371/journal.pgen.1006078

39. Roberts R., Chang C.C., Hadley T. Genetic risk stratification: a paradigm shift in prevention of coronary artery disease. JACC Basic Transl Sci. 2021;6(3):287-304. doi 10.1016/j.jacbts.2020.09.004

40. Ryzhkova O.P., Kardymon O.L., Prokhorchuk E.B., Konovalov F.A., Maslennikov A.B., Stepanov V.A., Afanasyev A.A., … Kostare va A.A., Pavlov A.E., Golubenko M.V., Polyakov A.V., Kutsev S.I. Guidelines for the interpretation of massive parallel sequenc ing variants (update 2018, v2). Med Genet. 2019;18(2):3-23. doi 10.25557/2073-7998.2019.02.3-23 (in Russian)

41. Senftleber N.K., Andersen M.K., Jørsboe E., Stæger F.F., Nøhr A.K., Garcia-Erill G., Meisner J., … Jørgensen M.E., Zeggini E., Moltke I., Hansen T., Albrechtsen A. GWAS of lipids in Greenlanders finds as sociation signals shared with Europeans and reveals an independent PCSK9 association signal. Eur J Hum Genet. 2024;32(2):215-223. doi 10.1038/s41431-023-01485-8

42. Shakhtshneider E., Ivanoshchuk D., Timoshchenko O., Orlov P., Semaev S., Valeev E., Goonko A., Ladygina N., Voevoda M. Analysis of rare variants in genes related to lipid metabolism in patients with familial hypercholesterolemia in Western Siberia (Russia). J Pers Med. 2021;11(11):1232. doi 10.3390/jpm11111232

43. Shim S.Y., Yoon H.Y., Yee J., Han J.M., Gwak H.S. Association be tween ABCA1 gene polymorphisms and plasma lipid concentration: a systematic review and meta-analysis. J Pers Med. 2021;11(9):883. doi 10.3390/jpm11090883

44. Simonen P., Öörni K., Sinisalo J., Strandberg T.E., Wester I., Gylling H. High cholesterol absorption: a risk factor of atherosclerotic cardio vascular diseases? Atherosclerosis. 2023;376:53-62. doi 10.1016/j.atherosclerosis.2023.06.003

45. Tada H., Kojima N., Takamura M., Kawashiri M.A. Sitosterolemia. Adv Clin Chem. 2022;110:145-169. doi 10.1016/bs.acc.2022.06.006

46. Toft-Nielsen F., Emanuelsson F., BennM. Familial hypercholesterolemia prevalence among ethnicities – systematic review and meta-analysis. Front Genet. 2022;13:840797. doi 10.3389/fgene.2022.840797

47. Tokgozoglu L., Kayikcioglu M. Familial hypercholesterolemia: global burden and approaches. Curr Cardiol Rep. 2021;23(10):151. doi 10.1007/s11886-021-01565-5

48. Totoń-Żurańska J., Wołkow P., Kapusta M., Wójcik M., Starzyk J., Kawalec E., Idzior-Waluś B., Waluś-Miarka M. Targeted sequenc ing of a gene panel in patients with familial hypercholesterolemia from Southern Poland. Pol Arch Intern Med. 2023;133(6):16417. doi 10.20452/pamw.16417

49. Valdivia A., Luque F.J., Llabrés S. Binding of cholesterol to the N-ter minal domain of the NPC1L1 transporter: analysis of the epimerization-related binding selectivity and loop mutations. J Chem Inf Model. 2023;64(1):189-204. doi 10.1021/acs.jcim.3c01319

50. Yoon H.J., Lee Y., Jeong J., Jang S., Lee H.H., Kim G.S. Binding free energy of several sterols to the N‐terminal domain of Nie mann‐Pick C1‐like 1 protein due to mutation: molecular dynamics study. J Chin Chem Soc. 2023;70(3):539-546. doi 10.1002/jccs.202200315

51. Yu X.H., Tang C.K. ABCA1, ABCG1, and cholesterol homeostasis. In: Zheng L. (Ed.) HDL Metabolism and Diseases. Advances in Ex perimental Medicine and Biology. Vol. 1377. Springer, Singapore, 2022;95-107. doi 10.1007/978-981-19-1592-5_7

52. Zhang R., Liu W., Zeng J., Meng J., Shi L., Yang S., Chang J., Wang C., Xing K., Wen J., Liu N., Liang B., Xing D. Recent advances in the screening methods of NPC1L1 inhibitors. Biomed Pharmacother. 2022;155:113732. doi 10.1016/j.biopha.2022.113732